Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive HF
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Breast
DISEASE(S): Breast Cancer
SUBMITTER: Steven Angus
LAB HEAD: Gary Johnson
PROVIDER: PXD021865 | Pride | 2021-04-09
REPOSITORIES: Pride
Angus Steven P SP Stuhlmiller Timothy J TJ Mehta Gaurav G Bevill Samantha M SM Goulet Daniel R DR Olivares-Quintero J Felix JF East Michael P MP Tanioka Maki M Zawistowski Jon S JS Singh Darshan D Sciaky Noah N Chen Xin X He Xiaping X Rashid Naim U NU Chollet-Hinton Lynn L Fan Cheng C Soloway Matthew G MG Spears Patricia A PA Jefferys Stuart S Parker Joel S JS Gallagher Kristalyn K KK Forero-Torres Andres A Krop Ian E IE Thompson Alastair M AM Murthy Rashmi R Gatza Michael L ML Perou Charles M CM Earp H Shelton HS Carey Lisa A LA Johnson Gary L GL
NPJ breast cancer 20210512 1
Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site inhibitors like lapatinib, commonly lack durability because of adaptive changes in the tumor leading to resistance. HER2+ cell line responses to inhibition with lapatinib were analyzed by RNAseq and ChI ...[more]